SM
AUTL

Sabby Management’s Autolus Therapeutics AUTL Stock Holding History

Sabby Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-409
Closed -$268K – 191
2021
Q3 		$268K Buy
+409
New +$2.58K 0.04% 136

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Sabby Management's AUTL Position: Q1 2022 in Review

Sabby Management sold out of Autolus Therapeutics (AUTL) in Q1 2022, closing a stake of 137,239 shares — an estimated $712K sold.

Sabby Management first reported a position in AUTL in Q1 2021 and held it in 4 quarters. The position peaked at $3.01M in Q1 2021. 66 funds tracked by Wall St. Rank hold AUTL as of Q1 2022.

  • Sabby Management reported no remaining Autolus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sabby Management sold 137,239 Autolus Therapeutics shares in Q1 2022, an estimated $712K.
  • Sabby Management first reported a position in Autolus Therapeutics in Q1 2021 and held it in 4 quarters.
  • Sabby Management's Autolus Therapeutics position peaked at $3.01M in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.